EP Patent

EP3255106A1 — A modified collagen

Assigned to Innocoll Pharmaceuticals Ltd · Expires 2017-12-13 · 8y expired

What this patent protects

The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

USPTO Abstract

The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (Bupivacaine Hydrochloride) · Pfizer

Patent Metadata

Patent number: EP3255106A1
Jurisdiction: EP
Classification: —
Expires: 2017-12-13
Drug substance claim: No
Drug product claim: No
Assignee: Innocoll Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.